Trial Profile

A Phase I Study of WP1066 in Children With Refractory and Progressive or Recurrent Malignant Brain Tumors (AflacST1901)

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 24 Mar 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs WP 1066 (Primary)
Indications Brain cancer; Diffuse intrinsic pontine glioma; Glioma; Medulloblastoma
Focus Adverse reactions
Acronyms AflacST1901

Most Recent Events

23 Mar 2023 According to a Moleculin Biotech media release, company to report topline results from this study.
17 Feb 2023 Status changed from recruiting to completed.
10 Nov 2022 According to an Moleculin Biotech media release, enrolled the final subject in the Phase 1 portion of the study.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com